Wednesday, July 8, 2026

Patent intelligence · US

US 11964019

Cochleates made with soy phosphatidylserine

granted A61KA61K31/12A61K31/122A61K31/685
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 8
Related coverage 1
Patent details — US 11964019

Quick answer

US 11964019 (Cochleates made with soy phosphatidylserine) is held by MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K31/12, A61K31/122, A61K31/685, A61K31/7036, A61K31/7048

More from MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12409227

    Cochleates made with soy phosphatidylserine

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Expires Sep 4, 2045

    granted
  2. US 11389407

    Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Expires Jul 14, 2042

    granted
  3. US 11123295

    Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Expires Sep 16, 2041

    granted
  4. US 10716860

    Cochleates made with soy phosphatidylserine

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Expires Jul 16, 2040

    granted
  5. US 10058521

    Omega-3 pentaenoic acid compositions and methods of use

    MATINAS BIOPHARMA INC. · Expires Aug 23, 2038

    granted
  6. US 9775907

    Cochleates made with soy phosphatidylserine

    MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. · Expires Sep 28, 2037

    granted
  7. US 8906964

    Methods of administering compositions comprising docosapentaenoic acid

    MATINAS BIOPHARMA INC. · Expires Dec 4, 2034

    granted

Related coverage

Frequently asked questions

What is US patent 11964019?

US 11964019 (Cochleates made with soy phosphatidylserine) is held by MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.. Status: granted. Granted Apr 23, 2024. Expires Apr 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11964019?

MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.

When does US 11964019 expire?

Our index shows an expiration date of Apr 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.